Cameron Platell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cameron Platell has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Katrina Spilsbury
Curtin School of Population Health, Faculty of Health Sciences, Curtin University, Perth, WA, Australia
4 shared publications Cheryl Penter
Colorectal Surgical Unit, St John of God Subiaco Hospital, Perth, Western Australia, Australia
3 shared publicationsGregory Makin
Colorectal Surgical Unit, St John of God Subiaco Hospital, Perth, Western Australia, Australia
3 shared publicationsMichael Levitt
Colorectal Surgical Unit, St John of God Subiaco Hospital, Perth, Western Australia, Australia
3 shared publicationsPatrick Ely Teloken
Colorectal Surgical Unit, St John of God Subiaco Hospital, University of Western Australia, Perth, Western Australia, Australia
3 shared publicationsPatrick Tan
Colorectal Surgical Unit, St John of God Subiaco Hospital, Perth, Western Australia, Australia
3 shared publications
Latest Publications
- Open Access
The Prognostic and Predictive Value of SOX2+ Cell Densities in Patients Treated for Colorectal Cancer
SOX2 (sex-determining region-Y homeobox-2) is a transcription factor essential for the maintenance of pluripotency and is also associated with stem-cell-like properties in preclinical cancer models. Our previous study on a cohort of stage III colon cancer patients demonstrated high SOX2+ cell densities were associated with poor prognosis. However, most patients were treated with adjuvant chemotherapy so the prognostic value of SOX2 could not be assessed independently from its value as a predictive marker for non-response to chemotherapy. This study aimed to assess whether SOX2 was a true prognostic marker or a marker for chemotherapy response in a historical cohort of patients, a high proportion of whom were chemotherapy-naïve. SOX2 immunostaining was performed on tissue micro-arrays containing tumor cores from 797 patients with stage II and III colorectal cancer. SOX2+ cell densities were then quantified with StrataQuest digital image analysis software. Overall survival was assessed using Kaplan–Meier estimates and Cox regression. It was found that high SOX2+ cell densities were not associated with poor overall survival. Furthermore, all patients had a significant improvement in survival after 5-fluorouracil (5-FU) treatment, irrespective of their SOX2+ cell density. Therefore, SOX2+ cell densities were not associated with prognosis or chemotherapy benefit in this study. This is in contrast to our previous study, in which most patients received oxaliplatin as part of their treatment, in addition to 5-FU. This suggests SOX2 may predict response to oxaliplatin treatment, but not 5-FU.
Open AccessThe Prognostic and Predictive Value of SOX2+ Cell Densities in Patients Treated for Colorectal Cancer
SOX2 (sex-determining region-Y homeobox-2) is a transcription factor essential for the maintenance of pluripotency and is also associated with stem-cell-like properties in preclinical cancer models. Our previous study on a cohort of stage III colon cancer patients demonstrated high SOX2+ cell densities were associated with poor prognosis. However, most patients were treated with adjuvant chemotherapy so the prognostic value of SOX2 could not be assessed independently from its value as a predictive marker for non-response to chemotherapy. This study aimed to assess whether SOX2 was a true prognostic marker or a marker for chemotherapy response in a historical cohort of patients, a high proportion of whom were chemotherapy-naïve. SOX2 immunostaining was performed on tissue micro-arrays containing tumor cores from 797 patients with stage II and III colorectal cancer. SOX2+ cell densities were then quantified with StrataQuest digital image analysis software. Overall survival was assessed using Kaplan–Meier estimates and Cox regression. It was found that high SOX2+ cell densities were not associated with poor overall survival. Furthermore, all patients had a significant improvement in survival after 5-fluorouracil (5-FU) treatment, irrespective of their SOX2+ cell density. Therefore, SOX2+ cell densities were not associated with prognosis or chemotherapy benefit in this study. This is in contrast to our previous study, in which most patients received oxaliplatin as part of their treatment, in addition to 5-FU. This suggests SOX2 may predict response to oxaliplatin treatment, but not 5-FU.
- 29 August 2018
- Published by Wiley in Anz Journal of Surgery
- Vol. 88 (10) , 1013-1016
Anal squamous cell carcinoma: are we improving outcomes?
Background: Anal squamous cell carcinoma (SCC) is a rare malignancy. The purpose of this study was to review a single institution's experience.Methods: All patients with anal SCC from St John of God Subiaco Hospital database were identified over a 10‐year period (2006–2016). Patients with stage 1 anal verge tumours underwent wide local excision, all remaining patients were offered chemoradiation (CRT) as an initial treatment modality (a fluorouracil‐based regimen in conjunction with mitomycin). Outcomes included recurrence, overall survival and survival following salvage surgery.Results: Forty‐seven patients were identified. Median age was 60 years and median follow‐up was 2.73 years. Five‐year rates of recurrence and overall survival were 35.8% (95% confidence interval (CI) 23.2–52.4%) and 65.4% (95% CI 47.0–78.7%), respectively. Locoregional failure occurred most commonly at the primary site. Eight patients underwent salvage abdominoperineal resection for persistent or recurrent disease, and four of these patients died within 5 years.Conclusion: CRT is a proven and reasonable effective approach in managing anal cancer. Observed recurrence and overall survival rates in this study resemble the published data. Despite newer methods of treatment being investigated, the treatment for anal SCC has not significantly changed in the past four decades and novel approaches are needed to further improve outcomes.
- 29 August 2018
- Published by Wiley in Anz Journal of Surgery
- Vol. 88 (10) , 1013-1016
Anal squamous cell carcinoma: are we improving outcomes?
Background: Anal squamous cell carcinoma (SCC) is a rare malignancy. The purpose of this study was to review a single institution's experience.Methods: All patients with anal SCC from St John of God Subiaco Hospital database were identified over a 10‐year period (2006–2016). Patients with stage 1 anal verge tumours underwent wide local excision, all remaining patients were offered chemoradiation (CRT) as an initial treatment modality (a fluorouracil‐based regimen in conjunction with mitomycin). Outcomes included recurrence, overall survival and survival following salvage surgery.Results: Forty‐seven patients were identified. Median age was 60 years and median follow‐up was 2.73 years. Five‐year rates of recurrence and overall survival were 35.8% (95% confidence interval (CI) 23.2–52.4%) and 65.4% (95% CI 47.0–78.7%), respectively. Locoregional failure occurred most commonly at the primary site. Eight patients underwent salvage abdominoperineal resection for persistent or recurrent disease, and four of these patients died within 5 years.Conclusion: CRT is a proven and reasonable effective approach in managing anal cancer. Observed recurrence and overall survival rates in this study resemble the published data. Despite newer methods of treatment being investigated, the treatment for anal SCC has not significantly changed in the past four decades and novel approaches are needed to further improve outcomes.
- 16 May 2017
- Published by Wiley in Anz Journal of Surgery
- Vol. 88 (5) , 445-449
Influence of primary site on metastatic distribution and survival in stage IV colorectal cancer
Background: To assess pattern distribution and prognosis of the three anatomical entities of metastatic colorectal cancer, and influence of treatment of metastases on survival.Methods: Patients presenting with stage IV colorectal cancer (synchronous group), or who developed metastatic recurrence (metachronous group) after initial curative treatment between January 2005 and August 2015 were reviewed. Right sided (cecum to transverse colon), left sided (splenic flexure to sigmoid colon) and rectal cancers were identified. Distribution of metastases were noted as hepatic, lung or peritoneal.Results: Of 374 patients, 276 were synchronous, 98 were metachronous. Metachronous group had a better 3‐year survival (54%, 95% CI: 42–64 versus 33%, 95% CI: 27–39, log rank P = 0.0038). There were equal numbers of right (n = 119), left (n = 115) and rectal cancers (n = 140). Rectal cancers had a higher metastatic recurrence, yet demonstrated better 3‐year survival (right colon 45%, 95% CI: 19–67, left colon 49%, 95% CI: 27–68, rectum 59%, 95% CI: 42–72, P = 0.39) due to higher proportions of metachronous patients undergoing treatment for metastases (40 versus 14%). Over half of all organ metastases spread to liver, with equal distribution from all three anatomical groups. Rectal cancers showed highest preponderance for lung metastases.Conclusion: Rectal cancers have a higher chance of recurring, with a higher metastatic rate to the lung, yet demonstrate better survival outcomes in metastatic colorectal cancer, reflecting the benefit of intervention for metastases.
- 16 May 2017
- Published by Wiley in Anz Journal of Surgery
- Vol. 88 (5) , 445-449
Influence of primary site on metastatic distribution and survival in stage IV colorectal cancer
Background: To assess pattern distribution and prognosis of the three anatomical entities of metastatic colorectal cancer, and influence of treatment of metastases on survival.Methods: Patients presenting with stage IV colorectal cancer (synchronous group), or who developed metastatic recurrence (metachronous group) after initial curative treatment between January 2005 and August 2015 were reviewed. Right sided (cecum to transverse colon), left sided (splenic flexure to sigmoid colon) and rectal cancers were identified. Distribution of metastases were noted as hepatic, lung or peritoneal.Results: Of 374 patients, 276 were synchronous, 98 were metachronous. Metachronous group had a better 3‐year survival (54%, 95% CI: 42–64 versus 33%, 95% CI: 27–39, log rank P = 0.0038). There were equal numbers of right (n = 119), left (n = 115) and rectal cancers (n = 140). Rectal cancers had a higher metastatic recurrence, yet demonstrated better 3‐year survival (right colon 45%, 95% CI: 19–67, left colon 49%, 95% CI: 27–68, rectum 59%, 95% CI: 42–72, P = 0.39) due to higher proportions of metachronous patients undergoing treatment for metastases (40 versus 14%). Over half of all organ metastases spread to liver, with equal distribution from all three anatomical groups. Rectal cancers showed highest preponderance for lung metastases.Conclusion: Rectal cancers have a higher chance of recurring, with a higher metastatic rate to the lung, yet demonstrate better survival outcomes in metastatic colorectal cancer, reflecting the benefit of intervention for metastases.
- 18 April 2016
- Published by Wiley in Anz Journal of Surgery
- Vol. 86 (6) , 454-458
Analysis of mortality in colorectal surgery in the Bi‐National Colorectal Cancer Audit
Background: In the last decade, there has been a significant increase in interest for public reporting of outcome data and performance comparison across institutions and surgeons. This study aims at comparing postoperative mortality after colorectal cancer surgery across units and individual consultants in Australia and New Zealand using funnel plots.Methods: The Bi‐National Colorectal Cancer Audit database was used. Unadjusted and adjusted funnel plots of inpatient mortality were constructed. Risk adjustment was based upon multivariable logistic regression models using purposeful covariate selection.Results: A total of 10 008 patients undergoing surgery for colorectal cancer from 56 surgical units and 90 consultants were identified. Overall inpatient mortality was 1.51%, corresponding to 1.1% for elective and 3.9% for urgent cases. Logistic regression identified age,American Society of Anesthesiologistsscore, urgent surgery and open surgery to be independently associated with inpatient mortality. Unadjusted and adjusted funnel plot analysis identified three (5.3%) units exceeding the inner limit and none exceeding the outer limit. Six (6.6%) consultants had inpatient mortality between the upper inner and outer limits and one (1.1%) between the inferior inner and outer limits. Upon adjustment, seven (7.7%) consultants had inpatient mortality between the inner and outer limit. Potential limitations of this study include: residual confounding being responsible for the association of open surgery and mortality; incomplete case‐mix adjustment resulting in outlier identification; and bias towards inclusion of larger institutions.Conclusion: Mortality figures in Australia and New Zealand are comparable to recently reported international data. The vast majority of units and consultants are performing within the expected boundaries.
- 18 April 2016
- Published by Wiley in Anz Journal of Surgery
- Vol. 86 (6) , 454-458
Analysis of mortality in colorectal surgery in the Bi‐National Colorectal Cancer Audit
Background: In the last decade, there has been a significant increase in interest for public reporting of outcome data and performance comparison across institutions and surgeons. This study aims at comparing postoperative mortality after colorectal cancer surgery across units and individual consultants in Australia and New Zealand using funnel plots.Methods: The Bi‐National Colorectal Cancer Audit database was used. Unadjusted and adjusted funnel plots of inpatient mortality were constructed. Risk adjustment was based upon multivariable logistic regression models using purposeful covariate selection.Results: A total of 10 008 patients undergoing surgery for colorectal cancer from 56 surgical units and 90 consultants were identified. Overall inpatient mortality was 1.51%, corresponding to 1.1% for elective and 3.9% for urgent cases. Logistic regression identified age,American Society of Anesthesiologistsscore, urgent surgery and open surgery to be independently associated with inpatient mortality. Unadjusted and adjusted funnel plot analysis identified three (5.3%) units exceeding the inner limit and none exceeding the outer limit. Six (6.6%) consultants had inpatient mortality between the upper inner and outer limits and one (1.1%) between the inferior inner and outer limits. Upon adjustment, seven (7.7%) consultants had inpatient mortality between the inner and outer limit. Potential limitations of this study include: residual confounding being responsible for the association of open surgery and mortality; incomplete case‐mix adjustment resulting in outlier identification; and bias towards inclusion of larger institutions.Conclusion: Mortality figures in Australia and New Zealand are comparable to recently reported international data. The vast majority of units and consultants are performing within the expected boundaries.
- 2 August 2015
- Published by Wiley in Anz Journal of Surgery
- Vol. 86 (1-2) , 49-53
Recurrence in patients with stage I colorectal cancer
Background Outcomes of patients with stage I colorectal cancer submitted to surgery with curative intent have not been thoroughly explored in contemporary series. Methods All patients with colon or rectal adenocarcinoma who underwent resection from the St John of God Hospital (1996–2013) and BioGrid (1991–2013) databases were identified. Patients submitted to local excision, polypectomies or neoadjuvant treatment were excluded. Outcomes included recurrence (combined local and systemic), recurrence‐free and overall survival, and survival after recurrence. Results A total of 1193 patients with stage I disease were included. Median age was 67 (interquartile range 59–75) and median follow‐up was 3.2 years (interquartile range 1.4–5.8). Five‐year recurrence rate was 7.1% (95% confidence interval (CI) 5.4–9.4%; 5.0% for colon and 11.1% for rectal cancer). Rectal location was an independent predictor of recurrence (hazard ratio (HR) 1.97, 95% CI 1.09–3.55; P = 0.024). Lymphovascular invasion was an independent predictor of recurrence only in patients with rectal cancer (HR 3.0, 95% CI 1.2–7.6; P = 0.018). Five‐year recurrence‐free survival was 83.2% (95% CI 80.3–85.4%). Age (HR 1.05, 95% CI 1.03–1.07; P < 0.001), elective surgery (HR 0.41, 95% CI 0.21–0.80; P = 0.011) and the American Society of Anesthesiologists (ASA) score (HR 3.08, 95% CI 1.51–6.31; P < 0.001) were independently associated with recurrence‐free survival. Median survival after recurrence was 41 months. Resection of recurrence was attempted in 39% of patients. Conclusion Patients with stage I colorectal cancers still have a clinically significant risk of recurrence. Rectal location is independently associated with higher recurrence. Age, elective surgery and ASA are independently associated with recurrence‐free survival. A significant proportion of patients with recurrence underwent further resection.
- 2 August 2015
- Published by Wiley in Anz Journal of Surgery
- Vol. 86 (1-2) , 49-53
Recurrence in patients with stage I colorectal cancer
Background Outcomes of patients with stage I colorectal cancer submitted to surgery with curative intent have not been thoroughly explored in contemporary series. Methods All patients with colon or rectal adenocarcinoma who underwent resection from the St John of God Hospital (1996–2013) and BioGrid (1991–2013) databases were identified. Patients submitted to local excision, polypectomies or neoadjuvant treatment were excluded. Outcomes included recurrence (combined local and systemic), recurrence‐free and overall survival, and survival after recurrence. Results A total of 1193 patients with stage I disease were included. Median age was 67 (interquartile range 59–75) and median follow‐up was 3.2 years (interquartile range 1.4–5.8). Five‐year recurrence rate was 7.1% (95% confidence interval (CI) 5.4–9.4%; 5.0% for colon and 11.1% for rectal cancer). Rectal location was an independent predictor of recurrence (hazard ratio (HR) 1.97, 95% CI 1.09–3.55; P = 0.024). Lymphovascular invasion was an independent predictor of recurrence only in patients with rectal cancer (HR 3.0, 95% CI 1.2–7.6; P = 0.018). Five‐year recurrence‐free survival was 83.2% (95% CI 80.3–85.4%). Age (HR 1.05, 95% CI 1.03–1.07; P < 0.001), elective surgery (HR 0.41, 95% CI 0.21–0.80; P = 0.011) and the American Society of Anesthesiologists (ASA) score (HR 3.08, 95% CI 1.51–6.31; P < 0.001) were independently associated with recurrence‐free survival. Median survival after recurrence was 41 months. Resection of recurrence was attempted in 39% of patients. Conclusion Patients with stage I colorectal cancers still have a clinically significant risk of recurrence. Rectal location is independently associated with higher recurrence. Age, elective surgery and ASA are independently associated with recurrence‐free survival. A significant proportion of patients with recurrence underwent further resection.
- 3 April 2014
- Published by Wiley in Anz Journal of Surgery
- Vol. 84 (12) , 960-964
Outcomes in patients undergoing urgent colorectal surgery
Background: Urgent surgery for acute intestinal presentations is generally associated with worse outcomes than elective procedures. This study assessed the outcomes of patients undergoing urgent colorectal surgery.Methods: Patients were identified from a prospective database. Surgery was classified as urgent when performed as soon as possible after resuscitation and usually within 24 h. Outcome measures included 30 days mortality, return to theatre, anastomotic leak and overall survival.Results: Two hundred forty‐nine patients were included in the analysis. Median age was 65 years (interquartile range 48–74). The most common presentations were obstruction (52.2%) and perforation (23.6%). Cancer was the disease process responsible for presentation in 47.8% of patients. Thirty‐day mortality was 6.8%. Age (odds ratio 1.08 95% confidence interval (CI) 1.02–1.15; P = 0.01), American Society of Anesthesiologists 4 (odds ratio 7.14 95% CI 1.67–30.4; P = 0.008) and cancer (odds ratio 6.61 95% CI 1.53–28.45; P = 0.011) were independent predictors of 30 days mortality. Relaparotomy was required in six (2.4%) cases. A primary anastomosis was performed in 156 (62.6%) patients. Anastomotic leak occurred in four (2.5%) patients. In patients with cancer, overall 5‐year survival was 28% (95% CI 19–37), corresponding to 54% (95% CI 35–70) for stages I and II, 50% (95% CI 24–71) for stage III and 6% (95% CI 1–17) for stage IV disease. Urgent surgery was independently associated with worse overall survival (hazard ratio 2.65; 95% CI 1.76–3.99; P < 0.001).Conclusion: In patients undergoing an urgent resection within a colorectal unit, performing a primary anastomosis is feasible and safe in the majority, relaparotomies are required in a minority and urgent surgery is an important predictor of worse prognosis in those with colorectal cancer.
- 3 April 2014
- Published by Wiley in Anz Journal of Surgery
- Vol. 84 (12) , 960-964
Outcomes in patients undergoing urgent colorectal surgery
Background: Urgent surgery for acute intestinal presentations is generally associated with worse outcomes than elective procedures. This study assessed the outcomes of patients undergoing urgent colorectal surgery.Methods: Patients were identified from a prospective database. Surgery was classified as urgent when performed as soon as possible after resuscitation and usually within 24 h. Outcome measures included 30 days mortality, return to theatre, anastomotic leak and overall survival.Results: Two hundred forty‐nine patients were included in the analysis. Median age was 65 years (interquartile range 48–74). The most common presentations were obstruction (52.2%) and perforation (23.6%). Cancer was the disease process responsible for presentation in 47.8% of patients. Thirty‐day mortality was 6.8%. Age (odds ratio 1.08 95% confidence interval (CI) 1.02–1.15; P = 0.01), American Society of Anesthesiologists 4 (odds ratio 7.14 95% CI 1.67–30.4; P = 0.008) and cancer (odds ratio 6.61 95% CI 1.53–28.45; P = 0.011) were independent predictors of 30 days mortality. Relaparotomy was required in six (2.4%) cases. A primary anastomosis was performed in 156 (62.6%) patients. Anastomotic leak occurred in four (2.5%) patients. In patients with cancer, overall 5‐year survival was 28% (95% CI 19–37), corresponding to 54% (95% CI 35–70) for stages I and II, 50% (95% CI 24–71) for stage III and 6% (95% CI 1–17) for stage IV disease. Urgent surgery was independently associated with worse overall survival (hazard ratio 2.65; 95% CI 1.76–3.99; P < 0.001).Conclusion: In patients undergoing an urgent resection within a colorectal unit, performing a primary anastomosis is feasible and safe in the majority, relaparotomies are required in a minority and urgent surgery is an important predictor of worse prognosis in those with colorectal cancer.
- 24 January 2014
- Published by Wiley in Anz Journal of Surgery
- Vol. 84 (10) , 763-768
Anastomotic leaks in colorectal surgery
Background: Anastomotic leaks are a serious complication of bowel surgery. This study aimed to evaluate the rate and severity, and identify risk factors for leaks in patients undergoing bowel anastomoses.Methods: Prospective evaluation was performed on patients undergoing bowel surgery within a colorectal surgical unit. Anastomotic leak was defined and graded according to severity. A nurse independently collected the information. Stepwise logistic regression analysis was performed.Results: Two thousand three hundred and sixty‐three patients underwent 2994 anastomoses. Their median age was 64 years. Seven per cent were emergency operations. Anastomotic leak occurred in 82 patients (2.7%). Sixty‐three per cent of leaks were managed with drainage or re‐operation. Ultra‐low anterior resection (ULAR) was associated with the highest subgroup leak rate (7.3%). In multivariable analysis, independent predictors for a leak included ‘other’ pathologies (iatrogenic injury, ischaemia, radiation enteritis) (P = 0.016, odds ratio (OR): 6.3, 95% confidence interval (CI): 1.4–28.0), ULAR (P = 0.001, OR: 8.5, 95% CI: 2.3–31.2) and the surgeon (A: P < 0.001, OR: 3.4, 95% CI: 2.1–5.6).Conclusion: Majority of predictors for anastomotic leak were fairly intuitive. Nonetheless, it was relevant to note the importance of the individual surgeon as an independent predictor for leaks.
- 24 January 2014
- Published by Wiley in Anz Journal of Surgery
- Vol. 84 (10) , 763-768
Anastomotic leaks in colorectal surgery
Background: Anastomotic leaks are a serious complication of bowel surgery. This study aimed to evaluate the rate and severity, and identify risk factors for leaks in patients undergoing bowel anastomoses.Methods: Prospective evaluation was performed on patients undergoing bowel surgery within a colorectal surgical unit. Anastomotic leak was defined and graded according to severity. A nurse independently collected the information. Stepwise logistic regression analysis was performed.Results: Two thousand three hundred and sixty‐three patients underwent 2994 anastomoses. Their median age was 64 years. Seven per cent were emergency operations. Anastomotic leak occurred in 82 patients (2.7%). Sixty‐three per cent of leaks were managed with drainage or re‐operation. Ultra‐low anterior resection (ULAR) was associated with the highest subgroup leak rate (7.3%). In multivariable analysis, independent predictors for a leak included ‘other’ pathologies (iatrogenic injury, ischaemia, radiation enteritis) (P = 0.016, odds ratio (OR): 6.3, 95% confidence interval (CI): 1.4–28.0), ULAR (P = 0.001, OR: 8.5, 95% CI: 2.3–31.2) and the surgeon (A: P < 0.001, OR: 3.4, 95% CI: 2.1–5.6).Conclusion: Majority of predictors for anastomotic leak were fairly intuitive. Nonetheless, it was relevant to note the importance of the individual surgeon as an independent predictor for leaks.
- 4 June 2013
- Published by Wiley in Anz Journal of Surgery
- Vol. 84 (1-2) , 85-90
Influence of local recurrence on survival in patients with rectal cancer
Recent trials on rectal cancer have demonstrated significant improvements in local recurrence without improvements in overall survival. The aim of this paper was to define the influence of local recurrence on survival in a prospective series of patients who underwent R0 or R1 resections for rectal cancer. Patients presenting with rectal cancer from 1996 to 2012 were prospectively audited. The study included patients who underwent an R0 or R1 resection. Local recurrence was defined as cancer regrowth detected in the pelvis regardless of whether or not new metastases were found elsewhere. Kaplan-Meier curves, smoothed hazard functions and Cox models using both time since diagnosis and age as the time scale were used to define the influence of local recurrence on overall survival. The study involved 483 patients, of mean age 66 years (standard deviation = 13) and a median follow-up of 5.2 years. The results at 5 years were overall survival 71% (95% confidence interval (CI) 66-75), local recurrence 7% (95% CI 5-10) and distant recurrence 18% (95% CI 14-22). Patients diagnosed with local recurrence died faster than patients diagnosed with either distant recurrence or no recurrence, and this was particularly obvious for younger patients (local hazard ratio (HR) 54, 95% CI 12-253 and distant HR19, 95% CI 4-80). Local recurrence that developed early following surgery also had worse survival outcomes. Within this cohort of rectal cancer patients, the early development of local recurrence was the single most important indicator of a reduced survival, and carried a worse prognosis than the development of distant metastases alone.
- 4 June 2013
- Published by Wiley in Anz Journal of Surgery
- Vol. 84 (1-2) , 85-90
Influence of local recurrence on survival in patients with rectal cancer
Recent trials on rectal cancer have demonstrated significant improvements in local recurrence without improvements in overall survival. The aim of this paper was to define the influence of local recurrence on survival in a prospective series of patients who underwent R0 or R1 resections for rectal cancer. Patients presenting with rectal cancer from 1996 to 2012 were prospectively audited. The study included patients who underwent an R0 or R1 resection. Local recurrence was defined as cancer regrowth detected in the pelvis regardless of whether or not new metastases were found elsewhere. Kaplan-Meier curves, smoothed hazard functions and Cox models using both time since diagnosis and age as the time scale were used to define the influence of local recurrence on overall survival. The study involved 483 patients, of mean age 66 years (standard deviation = 13) and a median follow-up of 5.2 years. The results at 5 years were overall survival 71% (95% confidence interval (CI) 66-75), local recurrence 7% (95% CI 5-10) and distant recurrence 18% (95% CI 14-22). Patients diagnosed with local recurrence died faster than patients diagnosed with either distant recurrence or no recurrence, and this was particularly obvious for younger patients (local hazard ratio (HR) 54, 95% CI 12-253 and distant HR19, 95% CI 4-80). Local recurrence that developed early following surgery also had worse survival outcomes. Within this cohort of rectal cancer patients, the early development of local recurrence was the single most important indicator of a reduced survival, and carried a worse prognosis than the development of distant metastases alone.
- 25 January 2013
- Published by Wiley in Colorectal Disease
- Vol. 15 (2) , 164-168
Cancer auditing – how accurate are your data?
Aim Human involvement in the collection and entering of information into a database leads to a degree of error. The aim of this study was to assess the concordance between two individuals blinded from each other who independently collected information on the same set of patients and entered it into a colorectal neoplasia database.Method A colorectal research nurse and a surgeon independently maintained an electronic database on all new patients admitted with colorectal neoplasia under the surgeon over a 5‐year period. Twenty‐three key endpoints were selected from the database in order to determine the agreement between the two observers. The κ statistic (for nominal and ordinal data) and the concordance correlation coefficient (for interval data) were used to determine the level of agreement between the two data sets.Results Both observers recorded 432 new referrals during this period. There was only complete concordance between the two databases with respect to the number of new patients and returns to theatre within 30 days. Nonetheless, there was almost perfect concordance between the two data sets for a majority of the endpoints. The most important areas of variance were in the length of stay (κ = 0.78), the American Society of Anesthesiology grade (κ = 0.41), emergency surgery (κ = 0.36), nodal staging (κ = 0.54) and time to recurrence (κ = 0.77).Conclusion This study highlights a number of important areas of data inaccuracy in a prospective colorectal database. The inaccuracies were due to observer bias, issues of data interpretation, or just difficulty in collecting the information accurately.
- 25 January 2013
- Published by Wiley in Colorectal Disease
- Vol. 15 (2) , 164-168
Cancer auditing – how accurate are your data?
Aim Human involvement in the collection and entering of information into a database leads to a degree of error. The aim of this study was to assess the concordance between two individuals blinded from each other who independently collected information on the same set of patients and entered it into a colorectal neoplasia database.Method A colorectal research nurse and a surgeon independently maintained an electronic database on all new patients admitted with colorectal neoplasia under the surgeon over a 5‐year period. Twenty‐three key endpoints were selected from the database in order to determine the agreement between the two observers. The κ statistic (for nominal and ordinal data) and the concordance correlation coefficient (for interval data) were used to determine the level of agreement between the two data sets.Results Both observers recorded 432 new referrals during this period. There was only complete concordance between the two databases with respect to the number of new patients and returns to theatre within 30 days. Nonetheless, there was almost perfect concordance between the two data sets for a majority of the endpoints. The most important areas of variance were in the length of stay (κ = 0.78), the American Society of Anesthesiology grade (κ = 0.41), emergency surgery (κ = 0.36), nodal staging (κ = 0.54) and time to recurrence (κ = 0.77).Conclusion This study highlights a number of important areas of data inaccuracy in a prospective colorectal database. The inaccuracies were due to observer bias, issues of data interpretation, or just difficulty in collecting the information accurately.
- Open Access
- 21 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 227
Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features
Background: Most previous studies of the CpG island methylator phenotype (CIMP) in colorectal cancer (CRC) have been conducted on a relatively small numbers of CpG sites. In the present study we performed comprehensive DNA methylation profiling of CRC with the aim of characterizing CIMP subgroups. Methods: DNA methylation at 1,505 CpG sites in 807 cancer-related genes was evaluated using the Illumina GoldenGate® methylation array in 28 normal colonic mucosa and 91 consecutive CRC samples. Methylation data was analyzed using unsupervised hierarchical clustering. CIMP subgroups were compared for various clinicopathological and molecular features including patient age, tumor site, microsatellite instability (MSI), methylation at a consensus panel of CpG islands and mutations in BRAF and KRAS. Results: A total of 202 CpG sites were differentially methylated between tumor and normal tissue. Unsupervised hierarchical clustering of methylation data from these sites revealed the existence of three CRC subgroups referred to as CIMP-low (CIMP-L, 21% of cases), CIMP-mid (CIMP-M, 14%) and CIMP-high (CIMP-H, 65%). In comparison to CIMP-L tumors, CIMP-H tumors were more often located in the proximal colon and showed more frequent mutation of KRAS and BRAF (P < 0.001). Conclusions: Comprehensive DNA methylation profiling identified three CRC subgroups with distinctive clinicopathological and molecular features. This study suggests that both KRAS and BRAF mutations are involved with the CIMP-H pathway of CRC rather than with distinct CIMP subgroups.
- 21 May 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 227
Open AccessComprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features
Background: Most previous studies of the CpG island methylator phenotype (CIMP) in colorectal cancer (CRC) have been conducted on a relatively small numbers of CpG sites. In the present study we performed comprehensive DNA methylation profiling of CRC with the aim of characterizing CIMP subgroups. Methods: DNA methylation at 1,505 CpG sites in 807 cancer-related genes was evaluated using the Illumina GoldenGate® methylation array in 28 normal colonic mucosa and 91 consecutive CRC samples. Methylation data was analyzed using unsupervised hierarchical clustering. CIMP subgroups were compared for various clinicopathological and molecular features including patient age, tumor site, microsatellite instability (MSI), methylation at a consensus panel of CpG islands and mutations in BRAF and KRAS. Results: A total of 202 CpG sites were differentially methylated between tumor and normal tissue. Unsupervised hierarchical clustering of methylation data from these sites revealed the existence of three CRC subgroups referred to as CIMP-low (CIMP-L, 21% of cases), CIMP-mid (CIMP-M, 14%) and CIMP-high (CIMP-H, 65%). In comparison to CIMP-L tumors, CIMP-H tumors were more often located in the proximal colon and showed more frequent mutation of KRAS and BRAF (P < 0.001). Conclusions: Comprehensive DNA methylation profiling identified three CRC subgroups with distinctive clinicopathological and molecular features. This study suggests that both KRAS and BRAF mutations are involved with the CIMP-H pathway of CRC rather than with distinct CIMP subgroups.